Bliss GVS Pharma Ltd
NSE: BLISSGVS · Pharmaceuticals · sector
₹620.05NSE close 2026-10-26
Key numbers
Market cap₹6,576 cr
Price₹620.05
52w high / low₹740 / ₹118
P/E48.1xSector median 27.9x
P/B5.5xSector median 2.9x
Book value₹112.5
Dividend yield0.17%Sector median 0.48%
ROE12.1%Sector median 11.7%
ROCE17.5%Sector median 12.3%
OPM18.4%Sector median 14.0%
Debt / equity0.00xSector median 0.16x
EV/EBITDA34.7xSector median 18.6x
Interest cover29.4x
Current ratio4.02x
Sales growth 3y+7.2%Sector median +9.6%
Profit growth 3y+22.1%Sector median +13.3%
PEG2.25x
Last 12 months to Jun 2026, Consolidated. "Sector median" = middle value of 185 companies in Pharmaceuticals (P/E median leaves out loss-making companies). Tap ? for what a number means.
Things to know
- Cash ₹168 cr vs borrowings ₹3 cr (FY26): cash is higher (net cash).
- Borrowings fell in each of the last 3 years (₹98 cr → ₹3 cr).
- Operating profit covered interest 29.4x in the last 12 months.
- 95.77% of the promoters' shares are pledged (48.0% of all shares).
- Promoter holding rose by 14.68 percentage points in a year, to 50.07% (2026-09-30).
- Operating cash flow was below net profit in 1 of the last 5 years (FY23).
- Revenue was higher than a year earlier in 4 of the last 4 quarters.
- Other income was 44% of net profit in the last 12 months.
- Debtor days went from 192 (FY24) to 204 (FY26).
- Dividend paid in 5 of the last 5 financial years.
- Price ₹620.05 on 2026-10-26: -16.2% from the 52-week high, +425.5% from the 52-week low.
Plain facts from the filings, built by the same fixed rules for every company. A line appears only when the data for it is available. Not a view on the stock.
Charts
Weekly close · high ₹692.85 · low ₹113.55
RevenueNet profit
RevenueNet profit
Quarterly results
| ₹ cr | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 218 | 210 | 198 | 207 | 244 | 218 | 257 | 286 |
| EBITDA | 41 | 30 | 21 | 41 | 32 | 32 | 44 | 76 |
| OPM % | 19.1% | 14.2% | 10.7% | 19.9% | 13.0% | 14.8% | 17.3% | 26.8% |
| Other income | 5 | 15 | 12 | 35 | 20 | 18 | 11 | 10 |
| Net profit | 24 | 24 | 16 | 43 | 27 | 23 | 36 | 50 |
| EPS (₹) | 2.31 | 2.27 | 1.47 | 4.08 | 2.58 | 2.20 | 3.37 | 4.73 |
| Revenue YoY | +12.3% | +3.7% | +29.8% | +37.6% | ||||
| Profit YoY | +12.3% | -2.2% | +129.0% | +16.4% |
Consolidated figures where filed. Latest quarter Jun 2026.
Profit & loss (yearly)
| ₹ cr | FY22 | FY23 | FY24 | FY25 | FY26 | TTM |
|---|---|---|---|---|---|---|
| Revenue | 747 | 752 | 770 | 810 | 927 | 1,005 |
| EBITDA | 45 | 117 | 121 | 127 | 162 | 185 |
| Net profit | 15 | 71 | 75 | 84 | 129 | 136 |
| EPS (₹) | 1.46 | 6.83 | 7.23 | 8.02 | 12.23 | 12.88 |
| Revenue growth | +0.6% | +2.5% | +5.1% | +14.5% | +20.6% | |
| Profit growth | +371.1% | +6.5% | +11.7% | +53.2% | +27.7% | |
| Dividend / share (₹) | 0.50 | 0.50 | 0.50 | 0.50 | 1.00 |
| Compounded growth | 3 years | 5 years | Last 12 months |
|---|---|---|---|
| Sales | +7.2% | +9.9% | +20.6% |
| Net profit | +22.1% | +13.5% | +27.7% |
| EPS | +21.4% | +13.0% | – |
| Share price | – | +115.6% (2y) | +292.3% |
Balance sheet
| ₹ cr | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|
| Shareholders' equity | – | 884 | 967 | 1,050 | 1,193 |
| Borrowings | – | 98 | 88 | 71 | 3 |
| Cash & equivalents | – | 108 | 216 | 213 | 168 |
| Total assets | – | 1,157 | 1,214 | 1,301 | 1,492 |
| Fixed assets | – | 370 | 362 | 397 | 451 |
| Capital work in progress | – | 3 | 8 | 21 | 6 |
| Investments | – | 3 | 4 | 4 | 4 |
| Receivables | – | 385 | 404 | 438 | 517 |
| Inventory | – | 103 | 118 | 126 | 151 |
| Payables | – | 86 | 61 | 71 | 104 |
Year-end figures from the March annual filing.
Cash flow
| ₹ cr | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|
| Cash from operations | 135 | 34 | 152 | 106 | 139 |
| Cash from investing | -93 | -8 | -133 | -75 | -38 |
| Cash from financing | -24 | -25 | -21 | -30 | -89 |
| Capex | 0 | 94 | 28 | 76 | 57 |
| Free cash flow | 135 | -59 | 124 | 30 | 82 |
Free cash flow = cash from operations − capex.
Ratios by year
| ₹ cr | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|
| ROE % | – | 8.0% | 7.8% | 8.0% | 10.8% |
| ROCE % | – | 11.9% | 11.7% | 11.9% | 16.9% |
| Debtor days | – | 187 | 192 | 198 | 204 |
| Inventory days | – | 94 | 113 | 111 | 129 |
| Payable days | – | 79 | 58 | 63 | 89 |
| Cash conversion cycle (days) | – | 202 | 247 | 246 | 244 |
| Working capital days | – | 245 | 309 | 292 | 280 |
Shareholding
| Holder | % (2026-09-30) |
|---|---|
| Promoters | 50.07% |
| FIIs | 5.03% |
| DIIs | 9.62% |
| of which Mutual funds | 0.00% |
| of which Insurance | 1.53% |
| Public (non-institutions) | 35.28% |
| Quarter | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 |
|---|---|---|---|---|---|---|---|---|
| Promoters % | 35.10% | 35.29% | 35.44% | 35.39% | 35.36% | 35.36% | 35.01% | 50.07% |
| Promoter group | % |
|---|---|
| Mates Visa Consultancy Private Limited | 47.95% |
| Anupam Rasayan India Limited | 2.12% |
| Kiran Pallavi Investments LLC | 0.00% |
| Jainam Intermediates Private Limited | 0.00% |
| ARIL Transmodal Logistic Private Limited | 0.00% |
| ARIL Fluorospeciality Private Limited | 0.00% |
| Anupam Japan GK | 0.00% |
| Anupam Europe AG | 0.00% |
| Anupam USA LLC | 0.00% |
| Anupam General Trading FZE | 0.00% |
| Doriath S.A.R.L | 0.00% |
| Kansas HOLDCO INC. | 0.00% |
| Kansas HOLDOC 1, INC. | 0.00% |
| Jayhawk Fine Chemicals Corporation | 0.00% |
| Tanfac Industries Limited | 0.00% |
| Public holders above 1% | % |
|---|---|
| Clarus Capital I | 4.99% |
| Investor Education and Protection Fund Authority Ministry of Corporate Affairs | 2.46% |
| 360 ONE Pipe Fund | 1.99% |
| Coeus Global Opportunities Fund | 1.75% |
| Life Insurance Corporation of India | 1.53% |
| GEE BEE Securities Private Limited | 1.18% |
| Amit Ashok Thawani | 1.06% |
47,944 shareholders. Pledged: 95.77% of promoter shares.
Peers in Pharmaceuticals
| Company | Market cap | P/E | P/B | ROE | ROCE | OPM | Sales 3y | Div yield |
|---|---|---|---|---|---|---|---|---|
| SUNPHARMA | ₹4,17,478 cr | 34.5x | 5.0x | 15.5% | 18.7% | 28.6% | +10.0% | 0.94% |
| DIVISLAB | ₹2,39,825 cr | 82.1x | 14.3x | 18.4% | 23.0% | 34.7% | +10.8% | 0.34% |
| TORNTPHARM | ₹1,53,999 cr | 72.7x | 18.4x | 27.3% | 15.1% | 32.3% | +13.3% | 0.84% |
| ZYDUSLIFE | ₹1,15,808 cr | 25.9x | 4.3x | 17.7% | 16.8% | 27.2% | +16.4% | 0.95% |
| LAURUSLABS | ₹1,11,232 cr | 101.6x | 21.0x | 22.4% | 20.8% | 28.0% | +4.1% | 0.08% |
| CIPLA | ₹1,09,464 cr | 32.5x | 3.2x | 10.3% | 13.2% | 17.7% | +7.4% | 1.18% |
| DRREDDY | ₹1,09,460 cr | 33.9x | 2.9x | 9.0% | 10.1% | 15.5% | +11.0% | 0.61% |
| MANKIND | ₹95,486 cr | 46.7x | 5.9x | 13.4% | 13.8% | 25.1% | +17.7% | 0.04% |
| AUROPHARMA | ₹91,489 cr | 24.9x | 2.4x | 10.5% | 12.8% | 20.0% | +10.6% | 0.26% |
| BLISSGVS | ₹6,576 cr | 48.1x | 5.5x | 12.1% | 17.5% | 18.4% | +7.2% | 0.17% |
Dividends & corporate actions
| Ex-date | Action | Detail |
|---|---|---|
| 2026-07-08 | Dividend | Dividend - Re 1 Per Share |
| 2026-02-18 | Dividend | Interim Dividend - Re 0.50 Per Share |
| 2025-07-24 | Dividend | Annual General Meeting/Dividend - Rs 0.50 Per Share |
| 2024-07-18 | Dividend | Annual General Meeting/Dividend - Rs 0.50 Per Share |
| 2023-07-12 | Dividend | Annual General Meeting/Dividend - Re 0.50 Per Share |
| 2022-06-20 | Dividend | Annual General Meeting/ Dividend - Rs 0.50 Per Share |
| 2021-09-13 | Dividend | Annual General Meeting/Dividend - Rs 0.50 Per Share |
| 2020-09-17 | Dividend | Annual General Meeting/Dividend - Rs 0.50 Per Share |
| 2019-09-12 | Dividend | Annual General Meeting/Dividend - Re 1 Per Share |
| 2018-08-14 | Dividend | Annual General Meeting/Dividend- Re 1 Per Share |
| 2017-09-18 | Dividend | Annual General Meeting/Dividend - Re 0.60 Per Share (Book Closure Dates Revised) |
| 2016-09-06 | Dividend | Annual General Meeting/Dividend Re 0.50 Per Share |
| 2015-09-08 | Dividend | Annual General Meeting/ Dividend - Re 0.50/- Per Share (Book Closure Dates Revised) |
| 2015-02-24 | Dividend | Interim Dividend - Re 0.20 Per Share |
| 2014-08-13 | Dividend | Annual General Meeting / Final Dividend - Re 0.50/- Per Share |
| 2013-08-01 | Dividend | Annual General Meeting / Dividend Rs 0.40 Per Share |
| 2013-02-25 | Dividend | Interim Dividend Rs 0.30 Per Share |
| 2012-08-02 | Dividend | Annual General Meeting / Dividend Rs 0.40 Per Share |
| 2011-11-24 | Dividend | Interim Dividend Re.0.35 Per Share |
| 2011-07-14 | Dividend | Dividend-Re.0.30 Per Share |
Documents
- Annual report FY26
- Annual report FY25
- Annual report FY24
- Annual report FY23
- Annual report FY22
- Announcements NSE filings
- Latest results (data file) XBRL
- Announcements BSE filings
Links go to the original files on the exchange website.
About the company
| Sector | Healthcare |
| Industry | Pharmaceuticals |
| Sub-industry | Pharmaceuticals |
| Symbol | BLISSGVS |
| BSE code | 506197 |
| ISIN | INE416D01022 |
| Face value | ₹1.0 |
| Incorporated | – |
| Website | – |
| Plants (India / abroad) | – |
Data built 2026-10-22 from NSE company filings (XBRL: Integrated Filing - Financials + financial results), NSE shareholding & pledge data; price = NSE close 2026-10-26.